Dr. Jahanzeb on the Benefit of Pertuzumab Plus Trastuzumab in HER2+ Breast Cancer
April 5th 2018
Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the benefit of pertuzumab (Perjeta) plus trastuzumab (Herceptin) for patients with HER2-positive breast cancer.